SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-000848
Filing Date
2023-05-01
Accepted
2023-04-28 18:29:46
Documents
74
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 20-F aktx-20221231x20f.htm   iXBRL 20-F 2972079
2 EX-23.1 aktx-20221231xex23d1.htm EX-23.1 3126
3 EX-31.1 aktx-20221231xex31d1.htm EX-31.1 14569
4 EX-31.2 aktx-20221231xex31d2.htm EX-31.2 14481
5 EX-32.1 aktx-20221231xex32d1.htm EX-32.1 8444
6 EX-32.2 aktx-20221231xex32d2.htm EX-32.2 8194
  Complete submission text file 0001410578-23-000848.txt   9445780

Data Files

Seq Description Document Type Size
7 EX-101.SCH aktx-20221231.xsd EX-101.SCH 53573
8 EX-101.CAL aktx-20221231_cal.xml EX-101.CAL 39309
9 EX-101.DEF aktx-20221231_def.xml EX-101.DEF 242824
10 EX-101.LAB aktx-20221231_lab.xml EX-101.LAB 408269
11 EX-101.PRE aktx-20221231_pre.xml EX-101.PRE 370545
68 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20221231x20f_htm.xml XML 1607079
Mailing Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018
Business Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 20-F | Act: 34 | File No.: 001-36288 | Film No.: 23869094
SIC: 2834 Pharmaceutical Preparations